Pegcetacoplan

Introduction Overview

Generic Name

pegcetacoplan

Brand Name

Empaveli

Dosage Form

injection for subcutaneous use via an infusion pump or Empaveli injector (1080 mg/20 mL)

Drug Class

Selective immunosuppressants

Pharmacokinetics

Absorption:
Empaveli (pegcetacoplan) is administered subcutaneously using either an infusion pump or an on-body injector. Following subcutaneous administration, pegcetacoplan is absorbed via the lymphatic system into systemic circulation. The bioavailability after subcutaneous injection is significant, allowing therapeutic plasma concentrations to be achieved with a dosing regimen of twice weekly injections. The onset of action is sufficient to maintain continuous complement inhibition between doses. Injection site factors such as vascularization and local tissue characteristics can influence absorption rate; however, clinical studies report consistent pharmacokinetic profiles across patient populations using standardized injection techniques.

Distribution:
Pegcetacoplan, a PEGylated 40 kDa molecule, exhibits moderate volume of distribution, primarily confined to the vascular and interstitial spaces. The drug’s PEGylation prolongs circulation time by reducing renal clearance and proteolytic degradation. Pegcetacoplan does not extensively penetrate intracellular compartments due to its large molecular size and hydrophilicity. Protein binding studies show minimal nonspecific binding, which contributes to stable plasma levels. Distribution is not notably affected by patient age, sex, or mild to moderate renal impairment, per existing pharmacokinetic data.

Metabolism:
Pegcetacoplan undergoes enzymatic degradation primarily by proteolytic enzymes into smaller peptides and amino acids, which are then reutilized or excreted. The PEG moiety is not metabolized and is eliminated mainly via renal filtration. There is no evidence of cytochrome P450 enzyme involvement in pegcetacoplan metabolism, suggesting a low potential for metabolic drug-drug interactions. The metabolism is consistent regardless of disease state, including in patients with paroxysmal nocturnal hemoglobinuria (PNH) or complement-mediated nephropathies.

Elimination:
The elimination half-life of pegcetacoplan supports twice-weekly dosing to maintain therapeutic plasma concentrations. Pegcetacoplan’s elimination occurs through both renal and proteolytic degradation pathways. Renal clearance contributes to excretion of the PEG component and smaller metabolites. Due to its molecular size and subcutaneous route, pegcetacoplan is eliminated slowly, with steady-state concentrations achieved after repeated dosing. No dose adjustment is currently recommended based on renal or hepatic function, although clinical experience is limited in severe impairment. Clinical trials have not reported accumulation beyond expected pharmacokinetic predictions.

Overall, Empaveli demonstrates predictable subcutaneous absorption, stable distribution confined to the extracellular compartment, metabolism via proteolysis, and elimination through renal and proteolytic pathways supporting its efficacy in complement-mediated diseases with a manageable dosing schedule.

Dosage Forms

Available Dosage Forms:
Empaveli is supplied as an injection for subcutaneous use in a single-dose vial containing pegcetacoplan 1080 mg in 20 mL solution (54 mg/mL concentration). It is administered via two primary delivery methods:
- Infusion pump: allowing controlled subcutaneous infusion typically over 30 to 60 minutes.
- Empaveli injector: a compact, on-body single-use device delivering the full dose subcutaneously with a push-button activation for ease of use at home.

Dosages for Adults and Adolescents:
- For Paroxysmal Nocturnal Hemoglobinuria (PNH) in adults: The recommended dose is 1080 mg (one 20 mL vial) administered twice weekly subcutaneously.
- For C3 Glomerulopathy (C3G) and Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN):
- Adults (≥18 years): 1080 mg (20 mL) twice weekly subcutaneously.
- Adolescents (12 years to <18 years): Weight-based dosing:
- ≥50 kg: Initial doses 1080 mg (20 mL) twice weekly.
- 35 to <50 kg: Initial doses starting at 648 mg (12 mL), second dose 810 mg (15 mL), maintenance 810 mg twice weekly.
- <35 kg: Initial and second doses 540 mg (10 mL), maintenance 648 mg (12 mL) twice weekly.

Specific Patient Populations:
- Pediatric use under 12 years has not been established; safety and efficacy remain unknown.
- No dose adjustments have been definitively recommended for renal or hepatic impairment, though careful monitoring is advised.
- Women of childbearing potential require pregnancy testing prior to initiation; effective contraception is recommended during and for 40 days post-therapy.
- Breastfeeding is not recommended during treatment and for 40 days following the last dose.

Standard clinical guidelines emphasize adherence to twice-weekly dosing intervals, administration into appropriate subcutaneous sites (abdomen avoiding 1 inch around the navel, thighs, hips, or upper arms), and monitoring for adverse events or signs of hemolysis. Dose modifications in the event of adverse reactions or special clinical situations should be managed by the treating physician referencing the prescribing information.

Mechanism Of Action

Empaveli (pegcetacoplan) functions as a targeted inhibitor of the complement component C3, a central activator in the complement cascade integral to innate immunity. By binding to complement protein C3, pegcetacoplan prevents its proteolytic cleavage into C3a and C3b, crucial fragments responsible for downstream activation events. This unique mechanism halts the amplification of the complement cascade at the level of C3, thereby inhibiting both the formation of inflammatory mediators and the opsonization of cells leading to destruction.

At the molecular level, pegcetacoplan’s PEGylated structure enhances its stability and circulatory half-life, allowing sustained binding to C3 and preventing its cleavage by convertases. This action inhibits the generation of C3a, an anaphylatoxin involved in inflammatory signaling, and C3b, which tags cells for phagocytosis and contributes to the assembly of the membrane attack complex (MAC). By blocking C3 cleavage, pegcetacoplan impedes the formation of MAC and subsequent cell lysis, thereby protecting red blood cells from both intravascular and extravascular hemolysis.

Clinically, this mechanism is vital in paroxysmal nocturnal hemoglobinuria (PNH), a disorder characterized by complement-mediated destruction of red blood cells. Empaveli’s ability to inhibit C3 activation provides broader protection compared to other complement inhibitors such as eculizumab or ravulizumab that target further downstream at C5. By acting upstream, Empaveli can prevent both intravascular hemolysis (caused by MAC) and extravascular hemolysis (due to opsonization by C3 fragments), which remain uncontrolled by C5 inhibitors.

In complement-mediated renal diseases like C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis, excessive activation of C3 contributes to pathologic deposition of C3 fragments in glomeruli leading to inflammation and tissue injury. Pegcetacoplan’s blockade of C3 cleavage reduces the generation of inflammatory complement fragments and prevents deposition, thereby ameliorating renal damage and proteinuria.

Emerging clinical studies demonstrate pegcetacoplan's efficacy in reducing markers of hemolysis, improving anemia, and preserving renal function. Comparative analysis with other complement inhibitors highlights Empaveli’s novel mode of action that modulates a broader spectrum of complement activity by targeting the core component C3 rather than downstream elements, providing clinical benefits in diseases with complex complement dysregulation.

Pharmacological Actions

Selective inhibition of complement protein C3 activation, preventing cleavage into C3a and C3b.
Inhibition of both intravascular hemolysis and extravascular hemolysis of red blood cells in PNH.
Suppression of complement-mediated inflammation by blocking generation of anaphylatoxins.
Prevention of membrane attack complex formation and consequent cell lysis.
Reduction of pathogenic C3 fragment deposition in kidney glomeruli in complement-mediated nephropathies.
Immune system modulation without complete complement shutdown, allowing residual host defense.
PEGylation extends half-life, allowing sustained therapeutic plasma concentrations.
Subcutaneous route enables self-administration and improved patient convenience.
Interruption of classical, lectin, and alternative complement activation pathways at the C3 level.
Reduction of hemolysis-related symptoms including anemia, fatigue, and hemoglobinuria.

Therapeutic Or Clinical Uses

Treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults to reduce hemolysis.
Reduction of proteinuria and renal injury in adults and children (≥12 years) with C3 glomerulopathy (C3G).
Management of primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 years and older.
Prevention of both intravascular and extravascular red blood cell destruction in PNH.
Adjunct therapy for patients intolerant or with inadequate response to C5 inhibitors.
Potential to improve quality of life in PNH by reducing transfusion requirements and hemolysis symptoms.
Off-label investigational use in complement-mediated diseases involving dysregulated C3 activation.
Reduction of inflammation and complement-mediated tissue damage in renal diseases.
Use in patients requiring a subcutaneously administered complement inhibitor for chronic therapy.
Treatment option within restricted REMS program ensuring vaccination and monitoring.

Side Or Adverse Effects

Injection-site reactions including redness, pain, and swelling.
Infusion-site reactions such as erythema and discomfort.
Infections including upper respiratory tract infections, nasopharyngitis, and influenza.
Gastrointestinal symptoms like diarrhea and nausea.
Stomach (abdominal) pain.
Musculoskeletal pain including joint pain, and pain in arms and legs.
Electrolyte disturbances, notably hypokalemia (low potassium levels).
General symptoms such as tiredness (fatigue), cough, dizziness, and headache.
Rash and urticaria (hives) possibly related to hypersensitivity reactions.
Rare but serious allergic or anaphylactic reactions during infusion requiring immediate cessation.
Fever occurring commonly in patients with complement-mediated nephropathies.
Potential for severe infections caused by encapsulated bacteria like Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B.
Possible infusion-related systemic symptoms including nausea, vomiting, sweating, and anxiety.
Dizziness or fainting especially in context of infusion reactions.
Hypersensitivity reactions manifesting as facial swelling, chest pain, or respiratory symptoms.

Precautions

Ensure complete vaccination against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B at least two weeks prior to therapy initiation.
Monitor closely for signs of serious infection, particularly meningitis caused by encapsulated bacteria.
Consider pregnancy testing before treatment start; use effective contraception during therapy and for 40 days afterward.
Avoid use in patients with unresolved serious infections caused by encapsulated bacteria.
Discontinue therapy promptly if signs of serious infection or hypersensitivity occur and seek immediate medical care.
Monitor patients for signs of hemolysis for at least 8 weeks after discontinuing therapy to detect rebound hemolysis.
Use caution in patients with a history of allergic reactions to pegcetacoplan or any excipients.
Pregnant or breastfeeding women should use Empaveli only if clearly needed and after risk-benefit assessment.
Patients should be instructed on safe subcutaneous administration techniques if self-administering.
Avoid delaying vaccination in patients requiring urgent initiation; provide vaccines as soon as possible if therapy cannot be postponed.
Patients should carry the Patient Safety Card at all times during treatment and for 2 months after last dose.
Potential interference with coagulation laboratory tests such as activated partial thromboplastin time (aPTT) must be considered.
Notify healthcare providers of therapy before undergoing surgeries or invasive procedures due to infection risk.
Regular clinical and laboratory monitoring is advised to assess treatment efficacy and identify adverse effects.
Educate patients on recognizing symptoms of hemolysis, infection, or infusion reactions.

Warnings

Boxed warning for increased risk of serious and potentially fatal infections caused by encapsulated bacteria including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B.
Potential for life-threatening infusion-related reactions or anaphylaxis requiring immediate infusion discontinuation and emergency treatment.
Risk of serious infections persists during therapy and for weeks after treatment discontinuation; patients must be monitored accordingly.
Patients not fully vaccinated against the specified bacteria should receive vaccines prior to therapy unless urgent treatment is necessary.
Discontinuing Empaveli may precipitate severe hemolysis; patients require close monitoring for at least 8 weeks post-therapy.
May cause false prolongation of aPTT in coagulation tests due to interference with silica reagents.
Do not use in patients allergic to pegcetacoplan or formulation excipients.
Potential for hypersensitivity reactions including facial or throat swelling, respiratory distress, and hypotension during infusion.
Not established as safe or effective in children under 12 years of age.
Pregnancy and breastfeeding safety have not been established; potential fetal harm is possible.
Carry the Patient Safety Card as an essential precautionary measure during and after treatment.
Empaveli is only available through a restricted REMS program to ensure safe use.
Use caution in patients with prior history of severe infections or immunocompromised states.
Obtain prompt medical assessment for any signs of infection or allergic reaction during treatment.
Avoid abrupt discontinuation without medical supervision due to risk of rebound hemolysis.

Contraindication

Known hypersensitivity to pegcetacoplan or any components of the formulation.
Patients not vaccinated against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B without urgent need for therapy.
Active, unresolved serious infection caused by encapsulated bacteria.
Use in pediatric patients under 12 years due to unknown safety and efficacy.
Patients with history of serious allergic reactions to polyethylene glycol-containing products unless under close medical supervision.
Known hypersensitivity to any inactive ingredients such as sorbitol or sodium acetate may contraindicate use.
Situations where immunosuppression poses unacceptable risk (e.g., uncontrolled immunodeficiency).
Hypersensitivity or allergy to any component of the Empaveli injection formulation.

Drug Interactions

No specific pharmacokinetic interactions have been reported due to lack of cytochrome P450 metabolism.
Potential interaction with vaccines—live vaccines should be avoided or used cautiously due to immunosuppression.
May interfere with coagulation testing such as aPTT leading to falsely prolonged results; inform laboratory personnel accordingly.
Concurrent use with other complement inhibitors has not been extensively studied and requires clinical judgment.
Immunosuppressive concomitant therapies may increase infection risk when used together with Empaveli.
Agents affecting renal elimination might theoretically alter pegcetacoplan clearance but not clinically established.
Vaccination responsiveness may be altered due to complement inhibition; coordinate timing with healthcare providers.
No known interactions with commonly used medications such as antihypertensives or antibiotics have been documented.
Concomitant use with drugs causing hypokalemia should be monitored due to Empaveli-associated electrolyte disturbances.
Herbal supplements and over-the-counter drugs should be reviewed with healthcare provider to avoid unrecognized interactions.
Potential additive immunosuppression risk when combined with systemic corticosteroids or biologics.
Empaveli’s interference with coagulation tests requires informing providers if anticoagulants or antiplatelets are being used.
Monitor clinical status and laboratory markers when initiating or discontinuing drugs impacting immune function.

Preparations Of The Drug

Single-dose vial containing 1080 mg pegcetacoplan in 20 mL sterile solution (54 mg/mL concentration).
Formulated for subcutaneous injection, supplied with or without infusion pump compatible packaging.
Empaveli injector device, a compact, wearable on-body autoinjector delivering a subcutaneous dose upon activation.
Vial contains active ingredient pegcetacoplan and inactive ingredients including sorbitol, glacial acetic acid, sodium acetate trihydrate, and Water for Injection USP.
pH adjusted with sodium hydroxide and/or glacial acetic acid to achieve optimal stability and compatibility.
Store refrigerated between 2°C to 8°C (36°F to 46°F) in original carton protected from light.
Do not freeze or shake the vial; use only if solution is clear and free of particulate matter.
Each vial intended for single use; discard any unused portion.
Provided under the restricted Empaveli REMS program to ensure safe prescribing and patient education.
Packaging designed to support home administration by patient or caregiver with training.
Vials labeled with expiry date; do not use expired product.
Compatible with commercially available infusion pumps or the manufacturer’s dedicated Empaveli injector.
Available only by prescription from healthcare providers enrolled in the restricted distribution program.
Supplied by Apellis Pharmaceuticals, Inc., Waltham, MA, USA.
Not currently available as a generic formulation.